Summarize this content material to 1000 phrases Singaporean startup Mesh Bio has raised $3.5 million in a Collection A funding spherical led by East Ventures. The spherical was additionally participated by Elev8, Seed Capitals, and its different shareholders.
WHAT IT’S FOR
In an announcement, the corporate stated it’ll use its recent funds to scale the deployment of its options, significantly its flagship digital twin providing, throughout Hong Kong and Southeast Asia.
The World Well being Group revealed in 2019 that 76% of all deaths within the area had been attributed to noncommunicable illnesses similar to coronary heart illnesses and diabetes. Mesh Bio has a focused concentrate on each Indonesia and the Philippines the place continual illnesses are stated to be most prevalent and lethal. “Southeast Asia presents myriad unmet healthcare wants, and our focus is to deal with these gaps successfully,” stated CEO and co-founder Dr. Andrew Wu.
THE LARGER TREND
The most recent funding elevate comes three months after Mesh Bio secured a regulatory clearance from Singapore’s Well being Sciences Authority for HealthVector Diabetes. The digital twin-based software-as-a-medical machine can predict a 3-year onset danger of continual kidney illness in sufferers with kind 2 diabetes by utilizing medical knowledge pulled from hospital EMRs.
The digital twin resolution, which is an expanded providing on Mesh Bio’s DARA Well being Intelligence Platform, is now being trialled at Singapore Common Hospital, Tan Tock Seng Hospital, and chosen polyclinics in Singapore.
The event of HealthVector Diabetes was first reported in October.
Mesh Bio baggage $3.5M to carry digital twin tech to Hong Kong, Indonesia, Philippines
2 Mins Read